We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

38 hedge funds and large institutions have $296M invested in Fusion Pharmaceuticals Inc. Common Shares in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 37 → 38 (+1)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8% less capital invested

Capital invested by funds: $320M → $296M (-$24.1M)

Holders
38
Holders Change
+1
Holders Change %
+2.7%
% of All Funds
0.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
10
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$8.58M
2
AG
Artal Group
Luxembourg
+$6.3M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.34M
4
Victory Capital Management
Victory Capital Management
Texas
+$1.24M
5
SCM
Sio Capital Management
New York
+$897K

Top Sellers

Rank Fund Capital Flow
1
ASP
Adams Street Partners
Illinois
-$5.88M
2
CCP
Clough Capital Partners
Massachusetts
-$4.69M
3
PA
Perceptive Advisors
New York
-$3.34M
4
DM
Deerfield Management
New York
-$1.91M
5
Norges Bank
Norges Bank
Norway
-$588K
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
26
DekaBank Deutsche Girozentrale
Germany
$129K – – –
Millennium Management
27
Millennium Management
New York
$115K -$418K -35,784 -77%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$115K +$126K +10,745 New
LJAC
29
L.J. Altfest & Co
New York
$109K +$119K +10,139 New
TRCT
30
Tower Research Capital (TRC)
New York
$17K +$18.2K +1,558 New
PCM
31
Penserra Capital Management
California
$10K -$117 -10 -1%
Citigroup
32
Citigroup
New York
$9K -$5.34K -457 -36%
PHK
33
Point72 Hong Kong
Hong Kong
$3K – – –
S
34
SignatureFD
Georgia
$3K – – –
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$3K +$152 +13 +4%
Daiwa Securities Group
36
Daiwa Securities Group
Japan
$1K – – –
APA
37
American Portfolios Advisors
New York
$322 – – –
CCP
38
Clough Capital Partners
Massachusetts
– -$4.69M -399,399 Closed
DM
39
Deerfield Management
New York
– -$1.91M -162,378 Closed
Norges Bank
40
Norges Bank
Norway
– -$588K -50,000 Closed
CCM
41
CAAS Capital Management
New York
– -$272K -23,148 Closed
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
– -$115K -9,927 Closed
1
2

FUSN Hedge Fund Activity: Q1 2021 in Review

38 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2021, worth a combined $296M — down 7.5% from $320M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new FUSN positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 8 trimmed.

The largest buyer was 1832 Asset Management, opening a new position worth an estimated $8.58M. The largest seller was Adams Street Partners, cutting an estimated $5.88M.

  • 38 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2021, up from 37 in Q4 2020.
  • Funds reported $296M of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2021, down 7.5% quarter-over-quarter.
  • 6 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2021 and 5 closed out, a net change of +1 holder.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2021 was 1832 Asset Management, an estimated $8.58M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2021 was Adams Street Partners, an estimated $5.88M sold.

Based on aggregated 13F filings for Q1 2021.